Drug Profile
Dimostat - Shuttle Pharmaceuticals
Alternative Names: SP 1 161Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Shuttle Pharmaceuticals
- Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
- Mechanism of Action Ataxia telangiectasia mutated protein stimulants; Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Sep 2023 Shuttle Pharmaceuticals receives a issuance of a Canadian patent for its histone deacetylase (HDAC) inhibitor platform
- 03 Apr 2023 Shuttle Pharmaceuticals plans IND enabling for Head and neck cancer and Lung cancer (Shuttle Pharmaceuticals pipeline; March 2023)
- 20 Mar 2023 Dimostat is still in preclinical phase for Cancer in USA (Shuttle Pharmaceuticals pipeline; March 2023)